{"generic":"Safinamide","drugs":["Safinamide"],"mono":{"0":{"id":"931383-s-0","title":"Generic Names","mono":"Safinamide"},"1":{"id":"931383-s-1","title":"Dosing and Indications","sub":[{"id":"931383-s-1-4","title":"Adult Dosing","mono":"<ul><li>Safinamide has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union.<\/li><li><b>Parkinson's disease:<\/b> 50 mg ORALLY once daily; may increase to 100 mg\/day<\/li><\/ul>"},{"id":"931383-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients "},{"id":"931383-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> No adjustment is needed<\/li><li><b>Hepatic impairment, mild (Child-Pugh score 5 or 6):<\/b> No adjustment needed<\/li><li><b>Hepatic impairment, moderate (Child-Pugh score 7 to 9):<\/b> Use lower dose of 50 mg\/day<\/li><li><b>Hepatic impairment, severe (Child-Pugh score 10 to 15):<\/b> Contraindicated for use<\/li><li><b>Elderly:<\/b> No adjustment required; not studied in patients 75 years and older<\/li><\/ul>"},{"id":"931383-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Parkinson's disease<br\/>"}]},"3":{"id":"931383-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931383-s-3-9","title":"Contraindications","mono":"<ul><li>Albinism, retinal degeneration, uveitis, inherited retinopathy, or severe progressive diabetic retinopathy<\/li><li>Concomitant use of other MAOIs; discontinue use at least 7 days prior to initiating MAOI therapy<\/li><li>Concomitant use of pethidine; discontinue use at least 7 days prior to initiating pethidine<\/li><li>Hypersensitivity to safinamide or any component of the product<\/li><li>Severe hepatic impairment<\/li><\/ul>"},{"id":"931383-s-3-10","title":"Precautions","mono":"<ul><li>Hepatic:<\/li><li>-- Moderate hepatic impairment; dosage adjustment recommended; discontinue use if progresses to severe; use contraindicated in patients with severe hepatic impairment<\/li><li>Ophthalmic:<\/li><li>-- Ophthalmological history with increased risk for retinal effects (eg, family history of hereditary retinal disease, retinitis pigmentosa, active retinopathy, uveitis); increased risk for retinal degeneration; use not recommended<\/li><li>Psychiatric:<\/li><li>-- Impulse control disorders (eg, obsessive thoughts, compulsions, pathological gambling, hypersexuality, compulsive spending) may occur<\/li><li>Reproductive:<\/li><li>-- Women of childbearing potential; adequate contraception required during use<\/li><li>Concomitant Use:<\/li><li>-- Avoid concomitant use with fluoxetine or fluvoxamine and let 5 half-lives of the SSRI lapse prior to initiating use<\/li><li>-- Concomitant use with BCRP substrates with a Tmax of 2 hours or less (eg, pitavastatin, pravastatin, ciprofloxacin, methotrexate, topotecan, diclofenac, glyburide); allow an interval of at least 5 hours between dosing<\/li><li>-- Concomitant use with dextromethorphan not recommended<\/li><li>--When used as an adjunct to levodopa, exacerbation of preexisting dyskinesia and potentiation of levodopa side effects may occur; a levodopa dose reduction may be required; this effect was not observed in patients with early stage Parkinson disease<\/li><\/ul>"},{"id":"931383-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"931383-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931383-s-4","title":"Drug Interactions","sub":[{"id":"931383-s-4-13","title":"Contraindicated","mono":"<ul><li>Furazolidone (probable)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Linezolid (probable)<\/li><li>Meperidine (probable)<\/li><li>Methylene Blue (probable)<\/li><li>Moclobemide (probable)<\/li><li>Nialamide (probable)<\/li><li>Phenelzine (probable)<\/li><li>Procarbazine (probable)<\/li><li>Rasagiline (probable)<\/li><li>Selegiline (probable)<\/li><li>Tranylcypromine (probable)<\/li><\/ul>"}]},"5":{"id":"931383-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Neurologic:<\/b>Dyskinesia (1% to less than 10%), Insomnia (1% to less than 10%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction (0.01% to less than 0.1%), Prolonged QT interval (0.1% to less than 1%)<\/li><li><b>Dermatologic:<\/b>Basal cell carcinoma of skin (0.1% to less than 1%)<\/li><li><b>Hematologic:<\/b>Leukopenia (0.1% to less than 1%)<\/li><li><b>Psychiatric:<\/b>Impulse control disorder, Restlessness (0.1% to less than 1%)<\/li><li><b>Other:<\/b>Falls (1% to less than 10%)<\/li><\/ul>"},"6":{"id":"931383-s-6","title":"Drug Name Info","sub":{"2":{"id":"931383-s-6-19","title":"Class","mono":"Antiparkinsonian<br\/>"},"3":{"id":"931383-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"931383-s-7","title":"Mechanism Of Action","mono":"Safinamide is a selective and reversible MAO-B inhibitor that increases extracellular levels of dopamine in the striatum. Safinamide also inhibits voltage-gated sodium channels and modulates stimulated release of glutamate.<br\/>"},"8":{"id":"931383-s-8","title":"Pharmacokinetics","sub":[{"id":"931383-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1.8 to 2.8 hours<\/li><li>Bioavailability, Oral: 95%<\/li><\/ul>"},{"id":"931383-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, plasma: 88% to 90%<\/li><li>Vd: 165 L<\/li><\/ul>"},{"id":"931383-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: Primary site<\/li><li>Safinamide acid (major): Inactive<\/li><li>Inhibitor of BCRP in the small intestine.<\/li><\/ul>"},{"id":"931383-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 1.5% changed<\/li><li>Renal excretion: 76% changed; less than 10% unchanged<\/li><li>Total body clearance: 4.6 L\/hour<\/li><\/ul>"},{"id":"931383-s-8-27","title":"Elimination Half Life","mono":"20 to 30 hours <br\/>"}]},"9":{"id":"931383-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>Take with water; may be given with or without food.<br\/>"},"10":{"id":"931383-s-10","title":"Monitoring","mono":"Improvement in the signs and symptoms of Parkinson disease may indicate efficacy.<br\/>"},"13":{"id":"931383-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report new or increased compulsions, obsessive thoughts, pathological gambling, libido, hypersexuality, impulsive behaviors, or compulsive buying and spending,<\/li><li>Side effects may include insomnia, dyskinesia, somnolence, dizziness, headache, cataracts, orthostatic hypotension, nausea, and falls.<\/li><li>Instruct patient to skip a missed dose and resume normal dosing schedule.<\/li><\/ul>"}}}